Shamburg News · 8-K filed Nov 16, 2026, 4:03 PM EST

Aytu BioPharma to Be Acquired by Rosemont Pharmaceuticals in $2.70 Per Share Tender Offer

AYTU · AYTU BIOPHARMA, INC

  • Acquisition
  • Material agreement
  • Reg FD disclosure
  • Materiality: high

On November 16, 2026, Aytu BioPharma entered into an Agreement and Plan of Merger with Rosemont Pharmaceuticals Holdings and RoseApollo Merger Sub, under which Rosemont's subsidiary will commence a tender offer for all outstanding Aytu common shares at $2.70 per share in cash, followed by a second-step merger under DGCL Section 251(h). The agreement provides for a $2.4 million termination fee in specified circumstances and a February 14, 2027 outside date for consummating the offer. Certain officers, all directors and certain stockholders signed tender and support agreements concurrently with the merger agreement, and the company issued a press release announcing the transaction.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 7.01, 9.01, accession 0001437749-26-037155.

Written from the filing by Shamburg Markets. Figures are as reported by the company.